FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297093897> ?p ?o ?g. }

• W4297093897 endingPage "101667" @default.
• W4297093897 startingPage "101667" @default.
• W4297093897 abstract "<h2>Summary</h2><h3>Background</h3> There are currently limited systemic treatment options for patients with advanced neuroendocrine tumours (NETS) and the efficacy of existing treatments is sub-optimal. We evaluated the efficacy and safety of Tegafur/gimeracil/oteracil/potassium capsules (S-1)/Temozolomide with or without thalidomide for the treatment of NETS (STEM trial). <h3>Methods</h3> A randomised, controlled, open-label, phase 2 trial conducted at eight hospitals in China. Adults (≥18 years) with unresectable/metastatic, pancreatic or non-pancreatic NETS, with an Eastern Cooperative Oncology Group (ECOG) PS of 0–1, and progression on ≤2 previous therapies were randomised (1:1, using hierarchical block randomization with block length 4, stratified by pancreatic/non-pancreatic disease to receive S-1 40–60 mg orally twice daily on days 1–14 plus temozolomide 200 mg orally daily on days 10–14 in a 21-day cycle OR S-1 and temozolomide plus thalidomide orally nightly (100 mg on days 1–7, 200 mg on days 8–14, and 300 mg from day 15), until disease progression, death, intolerable toxicity, withdrawal of informed consent or at the investigator's discretion. The primary endpoint was objective response rate (ORR) by RECIST 1.1 in an intention-to-treat population. Safety was assessed in all patients who received treatment. The study was registered at ClinicalTrials.gov: NCT03204019 (pancreatic group) and NCT03204032 (non-pancreatic group). <h3>Findings</h3> Between March 23, 2017 and November 16, 2020, 187 patients were screened and 140 were randomly assigned to S-1/temozolomide plus thalidomide (n = 69) or S-1/temozolomide (<i>n =</i>71). After a median follow-up of 12·1 months (IQR: 8·4–16·6), the ORR was comparable in the S-1/temozolomide plus thalidomide and S-1/temozolomide groups 26·1% [95% CI 17·2–37·5] versus 25·4% [95% CI 16·7–36·6]; odds ratio: 1·03 [95% CI 0·48–2·22]; <i>P</i> = 0·9381). In the S-1/temozolomide plus thalidomide group, the most common grade 3–4 treatment-related adverse event was fatigue (2/68, 3%), and in the control group were thrombocytopenia and diarrhea (both 1/71, 2%). There were no treatment-related deaths in either group. <h3>Interpretation</h3> S-1/temozolomide with or without thalidomide leads to a comparable treatment response in patients with advanced/metastatic NETS. <h3>Funding</h3> This work was supported by CAMS Innovation Fund for Medical Sciences (CIFMS,2021-I2M-1-066, 2017-I2M-4-002, 2021-I2M-1-019, 2017-I2M-1-001), the National Natural Science Foundation of China (81972311, 82141127, 31970794,), the State Key Project on Infection Diseases of China (2017ZX10201021-007-003), the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2019PT310026), Sanming Project of Medicine in Shenzhen (SZSM202011010), and the State Key Laboratory Special fund from the Ministry of Science (2060204)." @default.
• W4297093897 created "2022-09-27" @default.
• W4297093897 creator A5010899234 @default.
• W4297093897 creator A5010942053 @default.
• W4297093897 creator A5016062532 @default.
• W4297093897 creator A5022548422 @default.
• W4297093897 creator A5027049354 @default.
• W4297093897 creator A5034845046 @default.
• W4297093897 creator A5036779163 @default.
• W4297093897 creator A5039920014 @default.
• W4297093897 creator A5040831668 @default.
• W4297093897 creator A5045223580 @default.
• W4297093897 creator A5048937704 @default.
• W4297093897 creator A5049798138 @default.
• W4297093897 creator A5054744470 @default.
• W4297093897 creator A5055003664 @default.
• W4297093897 creator A5055743417 @default.
• W4297093897 creator A5062179244 @default.
• W4297093897 creator A5064161818 @default.
• W4297093897 creator A5065037360 @default.
• W4297093897 creator A5065081259 @default.
• W4297093897 creator A5074642572 @default.
• W4297093897 creator A5076582862 @default.
• W4297093897 creator A5081351512 @default.
• W4297093897 creator A5082056296 @default.
• W4297093897 creator A5084815360 @default.
• W4297093897 creator A5088724949 @default.
• W4297093897 date "2022-12-01" @default.
• W4297093897 modified "2023-09-27" @default.
• W4297093897 title "S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial" @default.
• W4297093897 cites W1675957369 @default.
• W4297093897 cites W1994843088 @default.
• W4297093897 cites W2016494887 @default.
• W4297093897 cites W2019607817 @default.
• W4297093897 cites W2033172867 @default.
• W4297093897 cites W2082715008 @default.
• W4297093897 cites W2098785952 @default.
• W4297093897 cites W2103846273 @default.
• W4297093897 cites W2115686439 @default.
• W4297093897 cites W2117452560 @default.
• W4297093897 cites W2128879260 @default.
• W4297093897 cites W2135049144 @default.
• W4297093897 cites W2137142564 @default.
• W4297093897 cites W2150545505 @default.
• W4297093897 cites W2159009361 @default.
• W4297093897 cites W2209368665 @default.
• W4297093897 cites W2229244841 @default.
• W4297093897 cites W2263248967 @default.
• W4297093897 cites W2512663019 @default.
• W4297093897 cites W2608160487 @default.
• W4297093897 cites W2740320865 @default.
• W4297093897 cites W2747212876 @default.
• W4297093897 cites W2769251881 @default.
• W4297093897 cites W2797121391 @default.
• W4297093897 cites W2809847023 @default.
• W4297093897 cites W2896748530 @default.
• W4297093897 cites W2897549551 @default.
• W4297093897 cites W2904895170 @default.
• W4297093897 cites W2948271523 @default.
• W4297093897 cites W2986542121 @default.
• W4297093897 cites W3087682866 @default.
• W4297093897 cites W3193520062 @default.
• W4297093897 cites W4286298063 @default.
• W4297093897 doi "https://doi.org/10.1016/j.eclinm.2022.101667" @default.
• W4297093897 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36188432" @default.
• W4297093897 hasPublicationYear "2022" @default.
• W4297093897 type Work @default.
• W4297093897 citedByCount "0" @default.
• W4297093897 crossrefType "journal-article" @default.
• W4297093897 hasAuthorship W4297093897A5010899234 @default.
• W4297093897 hasAuthorship W4297093897A5010942053 @default.
• W4297093897 hasAuthorship W4297093897A5016062532 @default.
• W4297093897 hasAuthorship W4297093897A5022548422 @default.
• W4297093897 hasAuthorship W4297093897A5027049354 @default.
• W4297093897 hasAuthorship W4297093897A5034845046 @default.
• W4297093897 hasAuthorship W4297093897A5036779163 @default.
• W4297093897 hasAuthorship W4297093897A5039920014 @default.
• W4297093897 hasAuthorship W4297093897A5040831668 @default.
• W4297093897 hasAuthorship W4297093897A5045223580 @default.
• W4297093897 hasAuthorship W4297093897A5048937704 @default.
• W4297093897 hasAuthorship W4297093897A5049798138 @default.
• W4297093897 hasAuthorship W4297093897A5054744470 @default.
• W4297093897 hasAuthorship W4297093897A5055003664 @default.
• W4297093897 hasAuthorship W4297093897A5055743417 @default.
• W4297093897 hasAuthorship W4297093897A5062179244 @default.
• W4297093897 hasAuthorship W4297093897A5064161818 @default.
• W4297093897 hasAuthorship W4297093897A5065037360 @default.
• W4297093897 hasAuthorship W4297093897A5065081259 @default.
• W4297093897 hasAuthorship W4297093897A5074642572 @default.
• W4297093897 hasAuthorship W4297093897A5076582862 @default.
• W4297093897 hasAuthorship W4297093897A5081351512 @default.
• W4297093897 hasAuthorship W4297093897A5082056296 @default.
• W4297093897 hasAuthorship W4297093897A5084815360 @default.
• W4297093897 hasAuthorship W4297093897A5088724949 @default.
• W4297093897 hasConcept C126322002 @default.
• W4297093897 hasConcept C141071460 @default.
• W4297093897 hasConcept C143998085 @default.
• W4297093897 hasConcept C203092338 @default.

• next